This is a non-core endpoint: only basic statistics are computed.
Malignant neoplasms of independent (primary) multiple sites (controls excluding all cancers)
CD2_INDEPENDENT_MULTIPLE_SITES_NAS_EXALLC
No definition available.
Endpoint definition
↥
FinnGen phenotype data
individuals
Apply sex-specific rule None
Check conditions None
Check pre-conditions, main-only, mode, registry filters
2 out of 7 registries used, show all original rules.
-
Check minimum number of events None
-
Include endpoints None
-
Remove individuals based on genotype QC
16
CD2_INDEPENDENT_MULTIPLE_SITES_NAS_EXALLC
Control definitions
Control exclude
C3_CANCER
Extra metadata
Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
C97-C97
Name in latin
Neoplasmata maligna locis multis non dependentibus (primariis)
No upset plot: script not run.
No upset table: script not run.
Similar endpoints
↥List of similar endpoints to
Malignant neoplasms of independent (primary) multiple sites (controls excluding all cancers)
based on the number of shared cases.
Broader endpoints:
- Malignant neoplasms of independent (primary) multiple sites
- Malignant neoplasms of independent (primary) multiple sites
- Malignant neoplasms of independent (primary) multiple sites (controls excluding all cancers)
- Malignant neoplasm (controls excluding all cancers)
- Malignant neoplasm
Narrower endpoints:
Summary Statistics
↥Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 16 | 7 | 9 |
| Unadjusted prevalence (%) | 0.00 | 0.00 | 0.00 |
| Mean age at first event (years) | 60.40 | 49.69 | 68.74 |
Mortality
Not a core endpoint, no data to show.
Age distribution of first events
Year distribution of first events
Cumulative Incidence
Not a core endpoint, no data to show.
Correlations
↥
Index endpoint: CD2_INDEPENDENT_MULTIPLE_SITES_NAS_EXALLC – Malignant neoplasms of independent (primary) multiple sites (controls excluding all cancers)
GWS hits:
Survival analyses between endpoints
↥Not a core endpoint, no data to show.
Drugs most likely to be purchased after Malignant neoplasms of independent (primary) multiple sites (controls excluding all cancers)
↥Endpoint not on priority list, no data to show.